Utilizing daily interferon (alpha 2b) and ribavirin combination therapy in chronic hepatitis C: a preliminary report.

Z. Karasu, Ahmet Gurakar, C. Emmett, A. Jazzar, G. McMillon, S. Hulagu, H. Wright

Research output: Contribution to journalArticle

Abstract

The optimal dose, frequency and duration of interferon alpha 2b and ribavirin combination for the treatment of chronic hepatitis C is still not clear. Preliminary hepatitis C virus kinetic studies have suggested that daily interferon (IFN) is more advantageous than less frequent administration. This report documents the preliminary findings of an investigative protocol to evaluate the efficacy of long-term (12 month), daily IFN alpha 2b and ribavirin combination therapy for chronic hepatitis C patients, who have either relapsed (relapsers) or not responded (non-responders) to previous IFN therapy. METHODS: 25 non-cirrhotic HCV patients were enrolled in an attempt to treat protocol. Patients were administered 3 million units (MU) IFN alpha 2b subcutaneously (SQ) and ribavirin 1000-1200 mg PO on a daily basis. RESULTS: Four patients were removed from the protocol because of noncompliance. The remaining 21 patients (10 relapsers, 11 non-responders) were evaluated at the end of their 12th week of treatment. Twelve patients (57%) became HCV-RNA negative and nine patients (43%) remain positive at the end of this period. CONCLUSION: Although further studies on larger patient populations are necessary, our preliminary data suggests that daily IFN alpha 2b and ribavirin treatment is highly effective, especially among patients who have relapsed from previous IFN treatment.

Original languageEnglish (US)
Pages (from-to)573-577
Number of pages5
JournalJournal - Oklahoma State Medical Association
Volume92
Issue number12
StatePublished - 1999
Externally publishedYes

Fingerprint

interferon alfa-2b
Ribavirin
Chronic Hepatitis C
Interferons
Therapeutics

Cite this

Utilizing daily interferon (alpha 2b) and ribavirin combination therapy in chronic hepatitis C : a preliminary report. / Karasu, Z.; Gurakar, Ahmet; Emmett, C.; Jazzar, A.; McMillon, G.; Hulagu, S.; Wright, H.

In: Journal - Oklahoma State Medical Association, Vol. 92, No. 12, 1999, p. 573-577.

Research output: Contribution to journalArticle

Karasu, Z. ; Gurakar, Ahmet ; Emmett, C. ; Jazzar, A. ; McMillon, G. ; Hulagu, S. ; Wright, H. / Utilizing daily interferon (alpha 2b) and ribavirin combination therapy in chronic hepatitis C : a preliminary report. In: Journal - Oklahoma State Medical Association. 1999 ; Vol. 92, No. 12. pp. 573-577.
@article{f2955874725b473b90a6ca3f109080cd,
title = "Utilizing daily interferon (alpha 2b) and ribavirin combination therapy in chronic hepatitis C: a preliminary report.",
abstract = "The optimal dose, frequency and duration of interferon alpha 2b and ribavirin combination for the treatment of chronic hepatitis C is still not clear. Preliminary hepatitis C virus kinetic studies have suggested that daily interferon (IFN) is more advantageous than less frequent administration. This report documents the preliminary findings of an investigative protocol to evaluate the efficacy of long-term (12 month), daily IFN alpha 2b and ribavirin combination therapy for chronic hepatitis C patients, who have either relapsed (relapsers) or not responded (non-responders) to previous IFN therapy. METHODS: 25 non-cirrhotic HCV patients were enrolled in an attempt to treat protocol. Patients were administered 3 million units (MU) IFN alpha 2b subcutaneously (SQ) and ribavirin 1000-1200 mg PO on a daily basis. RESULTS: Four patients were removed from the protocol because of noncompliance. The remaining 21 patients (10 relapsers, 11 non-responders) were evaluated at the end of their 12th week of treatment. Twelve patients (57{\%}) became HCV-RNA negative and nine patients (43{\%}) remain positive at the end of this period. CONCLUSION: Although further studies on larger patient populations are necessary, our preliminary data suggests that daily IFN alpha 2b and ribavirin treatment is highly effective, especially among patients who have relapsed from previous IFN treatment.",
author = "Z. Karasu and Ahmet Gurakar and C. Emmett and A. Jazzar and G. McMillon and S. Hulagu and H. Wright",
year = "1999",
language = "English (US)",
volume = "92",
pages = "573--577",
journal = "The Journal of the Oklahoma State Medical Association",
issn = "0030-1876",
publisher = "Oklahoma State Medical Association",
number = "12",

}

TY - JOUR

T1 - Utilizing daily interferon (alpha 2b) and ribavirin combination therapy in chronic hepatitis C

T2 - a preliminary report.

AU - Karasu, Z.

AU - Gurakar, Ahmet

AU - Emmett, C.

AU - Jazzar, A.

AU - McMillon, G.

AU - Hulagu, S.

AU - Wright, H.

PY - 1999

Y1 - 1999

N2 - The optimal dose, frequency and duration of interferon alpha 2b and ribavirin combination for the treatment of chronic hepatitis C is still not clear. Preliminary hepatitis C virus kinetic studies have suggested that daily interferon (IFN) is more advantageous than less frequent administration. This report documents the preliminary findings of an investigative protocol to evaluate the efficacy of long-term (12 month), daily IFN alpha 2b and ribavirin combination therapy for chronic hepatitis C patients, who have either relapsed (relapsers) or not responded (non-responders) to previous IFN therapy. METHODS: 25 non-cirrhotic HCV patients were enrolled in an attempt to treat protocol. Patients were administered 3 million units (MU) IFN alpha 2b subcutaneously (SQ) and ribavirin 1000-1200 mg PO on a daily basis. RESULTS: Four patients were removed from the protocol because of noncompliance. The remaining 21 patients (10 relapsers, 11 non-responders) were evaluated at the end of their 12th week of treatment. Twelve patients (57%) became HCV-RNA negative and nine patients (43%) remain positive at the end of this period. CONCLUSION: Although further studies on larger patient populations are necessary, our preliminary data suggests that daily IFN alpha 2b and ribavirin treatment is highly effective, especially among patients who have relapsed from previous IFN treatment.

AB - The optimal dose, frequency and duration of interferon alpha 2b and ribavirin combination for the treatment of chronic hepatitis C is still not clear. Preliminary hepatitis C virus kinetic studies have suggested that daily interferon (IFN) is more advantageous than less frequent administration. This report documents the preliminary findings of an investigative protocol to evaluate the efficacy of long-term (12 month), daily IFN alpha 2b and ribavirin combination therapy for chronic hepatitis C patients, who have either relapsed (relapsers) or not responded (non-responders) to previous IFN therapy. METHODS: 25 non-cirrhotic HCV patients were enrolled in an attempt to treat protocol. Patients were administered 3 million units (MU) IFN alpha 2b subcutaneously (SQ) and ribavirin 1000-1200 mg PO on a daily basis. RESULTS: Four patients were removed from the protocol because of noncompliance. The remaining 21 patients (10 relapsers, 11 non-responders) were evaluated at the end of their 12th week of treatment. Twelve patients (57%) became HCV-RNA negative and nine patients (43%) remain positive at the end of this period. CONCLUSION: Although further studies on larger patient populations are necessary, our preliminary data suggests that daily IFN alpha 2b and ribavirin treatment is highly effective, especially among patients who have relapsed from previous IFN treatment.

UR - http://www.scopus.com/inward/record.url?scp=0033251349&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033251349&partnerID=8YFLogxK

M3 - Article

C2 - 10616260

AN - SCOPUS:0033251349

VL - 92

SP - 573

EP - 577

JO - The Journal of the Oklahoma State Medical Association

JF - The Journal of the Oklahoma State Medical Association

SN - 0030-1876

IS - 12

ER -